Terazosin
(NZMOFYDMGFQZLS-UHFFFAOYSA-N)
Structure
- SMILES
- COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1CCCO1.O.O.Cl
- Molecular Formula:
- C19H30ClN5O6
- Molecular Weight:
- 459.924
- Log P:
- 2.3143
- Hydrogen Bond Acceptor:
- 11
- Hydrogen Bond Donor:
- 4
- TPSA:
- 121.5
- CAS Number(s):
- 70024-40-7
Synonym(s)
1.
Terazosin
2.
A 45975
3.
Adecur
4.
Apo-Terazosin
5.
Deflox
6.
Dysalfa
7.
Flotrin
8.
Heitrin
9.
Hytrin
10.
Hytrin BPH
11.
Hytrine
12.
Magnurol
13.
Novo-Terazosin
14.
Nu-Terazosin
15.
PMS-Terazosin
16.
Sutif
17.
Tazusin
18.
Terazoflo
19.
Terazosin AZU
20.
Terazosin Hexal
21.
Terazosin hydrochloride
22.
Terazosina Alter
23.
Terazosina Kern
24.
Terazosina Qualix
25.
Zayasel
26.
ratio-Terazosin
27.
terazosin hydrochloride anhydrous
28.
terazosin, monohydrochloride, dihydrate
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Hypotension | FAERS: 99 | US FAERS | |
| 2 | Syncope | FAERS: 93 | US FAERS | |
| 3 | Dizziness | FAERS: 82 | US FAERS | |
| 4 | Headache | FAERS: 12 | US FAERS | |
| 5 | Nausea | FAERS: 10 | US FAERS | |
| 6 | Asthenia | FAERS: 9 | US FAERS | |
| 7 | Bradycardia | FAERS: 6 | US FAERS | |
| 8 | Pharmaceutical product complaint | FAERS: 6 | US FAERS | |
| 9 | Presyncope | FAERS: 6 | US FAERS | |
| 10 | Vomiting | FAERS: 6 | US FAERS | |
| 11 | Palpitations | FAERS: 5 | US FAERS | |
| 12 | Priapism | FAERS: 5 | US FAERS | |
| 13 | Atrial Fibrillation | FAERS: 4 | US FAERS | |
| 14 | Unevaluable event | FAERS: 4 | US FAERS | |
| 15 | Angina Pectoris | FAERS: 3 | US FAERS | |
| 16 | Blindness | FAERS: 3 | US FAERS | |
| 17 | Blood creatinine increased | FAERS: 3 | US FAERS | |
| 18 | Chest Pain | FAERS: 3 | US FAERS | |
| 19 | Dehydration | FAERS: 3 | US FAERS | |
| 20 | Drug dose omission | FAERS: 3 | US FAERS | |
| 21 | Drug ineffective | FAERS: 3 | US FAERS | |
| 22 | Medication Error | FAERS: 3 | US FAERS | |
| 23 | Pruritus | FAERS: 3 | US FAERS | |
| 24 | Unresponsive to stimuli | FAERS: 3 | US FAERS | |
| 25 | Amnesia | FAERS: 2 | US FAERS | |
| 26 | Arthralgia | FAERS: 2 | US FAERS | |
| 27 | Chest discomfort | FAERS: 2 | US FAERS | |
| 28 | Cyanosis | FAERS: 2 | US FAERS | |
| 29 | Diplopia | FAERS: 2 | US FAERS | |
| 30 | Erectile dysfunction | FAERS: 2 | US FAERS | |
| 31 | Fatigue | FAERS: 2 | US FAERS | |
| 32 | Incorrect dose administered | FAERS: 2 | US FAERS | |
| 33 | Joint swelling | FAERS: 2 | US FAERS | |
| 34 | Nocturia | FAERS: 2 | US FAERS | |
| 35 | Overdose | FAERS: 2 | US FAERS | |
| 36 | Pain | FAERS: 2 | US FAERS | |
| 37 | Pallor | FAERS: 2 | US FAERS | |
| 38 | Product quality issue | FAERS: 2 | US FAERS | |
| 39 | Shock | FAERS: 2 | US FAERS | |
| 40 | Tinnitus | FAERS: 2 | US FAERS | |
| 41 | Abdominal Pain | FAERS: 1 | US FAERS | |
| 42 | Agitation | FAERS: 1 | US FAERS | |
| 43 | Angioedema | FAERS: 1 | US FAERS | |
| 44 | Anorexia | FAERS: 1 | US FAERS | |
| 45 | Anorgasmia | FAERS: 1 | US FAERS | |
| 46 | Atelectasis | FAERS: 1 | US FAERS | |
| 47 | Back Pain | FAERS: 1 | US FAERS | |
| 48 | Benign Prostatic Hyperplasia | FAERS: 1 | US FAERS | |
| 49 | Blood chloride decreased | FAERS: 1 | US FAERS | |
| 50 | Blood creatine phosphokinase increased | FAERS: 1 | US FAERS | |
| 51 | Blood sodium decreased | FAERS: 1 | US FAERS | |
| 52 | Blood thyroid stimulating hormone decreased | FAERS: 1 | US FAERS | |
| 53 | Blood urea increased | FAERS: 1 | US FAERS | |
| 54 | Cerebrovascular accident | FAERS: 1 | US FAERS | |
| 55 | Compression fracture | FAERS: 1 | US FAERS | |
| 56 | Cor pulmonale | FAERS: 1 | US FAERS | |
| 57 | Demyelination | FAERS: 1 | US FAERS | |
| 58 | Diabetes Mellitus | FAERS: 1 | US FAERS | |
| 59 | Discomfort | FAERS: 1 | US FAERS | |
| 60 | Drooling | FAERS: 1 | US FAERS | |
| 61 | Drug screen positive | FAERS: 1 | US FAERS | |
| 62 | Drug toxicity | FAERS: 1 | US FAERS | |
| 63 | Dysuria | FAERS: 1 | US FAERS | |
| 64 | Epididymitis | FAERS: 1 | US FAERS | |
| 65 | Erythema | FAERS: 1 | US FAERS | |
| 66 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 67 | Flatulence | FAERS: 1 | US FAERS | |
| 68 | Floppy iris syndrome | FAERS: 1 | US FAERS | |
| 69 | Hypothyroidism | FAERS: 1 | US FAERS | |
| 70 | Immobile | FAERS: 1 | US FAERS | |
| 71 | Initial insomnia | FAERS: 1 | US FAERS | |
| 72 | Lethargy | FAERS: 1 | US FAERS | |
| 73 | Memory impairment | FAERS: 1 | US FAERS | |
| 74 | Mental status changes | FAERS: 1 | US FAERS | |
| 75 | Middle insomnia | FAERS: 1 | US FAERS | |
| 76 | Multiple System Atrophy | FAERS: 1 | US FAERS | |
| 77 | Myalgia | FAERS: 1 | US FAERS | |
| 78 | Myoclonus | FAERS: 1 | US FAERS | |
| 79 | No reaction on previous exposure to drug | FAERS: 1 | US FAERS | |
| 80 | Orthostatic hypertension | FAERS: 1 | US FAERS | |
| 81 | Orthostatic intolerance | FAERS: 1 | US FAERS | |
| 82 | Photophobia | FAERS: 1 | US FAERS | |
| 83 | Physical assault | FAERS: 1 | US FAERS | |
| 84 | Pneumonia | FAERS: 1 | US FAERS | |
| 85 | Poisoning | FAERS: 1 | US FAERS | |
| 86 | Product substitution issue | FAERS: 1 | US FAERS | |
| 87 | Rash erythematous | FAERS: 1 | US FAERS | |
| 88 | Residual urine volume | FAERS: 1 | US FAERS | |
| 89 | Somnolence | FAERS: 1 | US FAERS | |
| 90 | Suicide attempt | FAERS: 1 | US FAERS | |
| 91 | Tachycardia | FAERS: 1 | US FAERS | |
| 92 | Terminal dribbling | FAERS: 1 | US FAERS | |
| 93 | Throat irritation | FAERS: 1 | US FAERS | |
| 94 | Thrombocytopenia | FAERS: 1 | US FAERS | |
| 95 | Urinary Incontinence | FAERS: 1 | US FAERS | |
| 96 | Urinary Retention | FAERS: 1 | US FAERS | |
| 97 | Urinary tract infection | FAERS: 1 | US FAERS | |
| 98 | Urticaria | FAERS: 1 | US FAERS | |
| 99 | Visual Impairment | FAERS: 1 | US FAERS | |
| 100 | Visual disturbance | FAERS: 1 | US FAERS | |
| 101 | Weight decreased | FAERS: 1 | US FAERS | |
| 102 | treatment failure | FAERS: 1 | US FAERS |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.